



You've made the decision to switch your LMWH to Clexane

Use this simple checklist to support an efficient introduction within the Trust

**Step 1: Contact [ClexaneSupport@sanofi.com](mailto:ClexaneSupport@sanofi.com)** and provide the following information

- Estimated monthly volume per strength of LMWH
- Wholesaler details and local depot
- Account number

This will enable Sanofi to ensure that there is appropriate stock in the local area

**Step 2: Prescribing**

- Update the Electronic Prescribing System to enable Clexane (Enoxaparin) prescribing
- Remember that National Guidance recommends that biological medicines are prescribed by brand<sup>1-2</sup>
- Ensure the discharge letter states 'Clexane' to support primary care prescribers in the governance and safety of initiating and/or continuing the prescribing of Clexane
- Introduce Clexane into the Ward Stock/Clinic Stock
- Update formulary

**Step 3: Internal Communication**

- Use the internal communication system to ensure all HCPs are aware of the move to Clexane.
- Direct HCPs to [www.campus.sanofi/uk/products/thrombosis/clexane](http://www.campus.sanofi/uk/products/thrombosis/clexane) for access to information, education and support materials

**Step 4: HCP/Patient Support**

- Order an allocation of patient packs (includes sharps bin, patient booklet, patient card)
- Request HCP education/device training

Please [contact us](#) with any queries

1. NICE National Institute for Health and Care Excellence (NICE). 2022; British National Formulary – General guidance. Available at: <https://bnf.nice.org.uk/guidance/guidance-on-prescribing.html>. Date accessed: March 2023

2. Healthcare Improvement Scotland Org. (n.d). *Biosimilar medicines: A national prescribing framework*. [online] Available at: [https://www.healthcareimprovementscotland.org/our\\_work/technologies\\_and\\_medicines/programme\\_resources/biosimilar\\_medicines\\_framework.aspx](https://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/programme_resources/biosimilar_medicines_framework.aspx) [Accessed March 2023].

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple Store.  
Adverse events should also be reported to Sanofi Tel: 0800 0902314. Alternatively, send via email to [UK-drugsafety@sanofi.com](mailto:UK-drugsafety@sanofi.com)